アルツハイマー病に対する感受性の位置は,染色体10にある
A Myers1, P Holmans, H Marshall
1Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid, St. Louis, MO 63110, USA.
Science (New York, N.Y.)
|December 23, 2000
まとめ
研究者らは,染色体10に新しいアルツハイマー病のリスク遺伝子を特定しました. この発見は,APOE遺伝子を超えて,他の遺伝的要因が遅発アルツハイマー病に寄与することを示唆するので,重要なものです.
科学分野:
- 遺伝学 遺伝学とは
- 神経科学は神経科学である.
- 医学研究 医学研究
背景:
- アポリポタンパク質E (APOE) 遺伝子,特にAPOE4アレルは,遅発アルツハイマー病 (LOAD) の主要な既知の遺伝的リスク因子です.
- LOAD症例の有意な割合 (50%) は,APOE4アレルを持ちませんので,他の遺伝的感受性因子の存在を示しています.
- これらの追加の要因を特定することは,LOADの病原性の包括的な理解のために非常に重要です.
研究 の 目的:
- LOADに罹患した兄弟のペアで全ゲノムスクリーニングを行い,新しい感受性の位置を特定します.
- 既定のAPOE遺伝子を超えてアルツハイマー病の遺伝的危険因子を調査する.
- 染色体10にある新しいアルツハイマー病の場所の証拠を提供するためです.
主な方法:
- 2段階の全ゲノムスクリーニングは,LOADと診断された兄弟のペアを使用して行われました.
- 多点対数確率スコア (LOD) 分析を使用して,リンクを評価しました.
- D10S1225を含む遺伝マーカーを分析し,潜在的な感受性の位置を特定しました.
主要な成果:
- この研究では,染色体10にあるアルツハイマー病の感受性場所の有意な証拠が検出されました.
- 多点LODスコアは,第1段階 (266組) の2.48から第2段階 (429組) の3.83にD10S1225の近くで増加した.
- この特定された位置は,APOE遺伝子型に関係なく,アルツハイマー病のリスクに対する独立した効果を示しています.
結論:
- 染色体10に新しいアルツハイマー病の感受性の場所が特定されました.
- この位置は,APOEの遺伝子型に関係なく,LOADリスクに寄与する.
- この発見は,アルツハイマー病の複雑な遺伝的構造を強調し,非APOE遺伝的危険因子に関するさらなる研究への道を開きます.
関連する概念動画
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...